Webcast

Orthocell Limited Investor Briefing – 23 September

September 22, 2020

Orthocell Limited Investor Briefing – 23 September

Orthocell Limited (ASX: OCC) Webcast Replay

Orthocell Limited (ASX: OCC) is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance. 

As a part of our ‘Meet the CEOs’ series, Managing Director Paul Anderson provides valuable insights to the company, key markets and industry, and company’s future prospects.

Recorded on 23rd September 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to our Advisor team about this company

FEATURE SPEAKERS

PAUL ANDERSON

Managing Director - Orthocell Limited (ASX: OCC)

Orthocell Limited (ASX: OCC) is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance. Its product portfolio includes CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. The Company’s other major focus is TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue.

Speak to our Advisor team about this company



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.